---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046069"
form_type: "8-K"
ticker: "ICU"
cik: "0001831868"
company_name: "SeaStar Medical Holding Corp"
filed_at: "2025-03-27T23:59:59+00:00"
generated_at: "2026-05-24T04:14:46.866134+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch

## Summary
- Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.
- First net revenue of $0.1M from QUELIMMUNE pediatric AKI therapy approved via HDE in Q1 2024.
- NEUTRALIZE AKI pivotal trial enrolled 94 of 200 patients; added 14 sites in 2024.
- Raised ~$31M in capital and reduced debt; $6M registered direct financing completed Feb 2025.
- Cash and short-term investments $1.8M at Dec 31, 2024, before February financing.

## SEC filing metadata
- accession: 0000950170-25-046069
- form_type: 8-K
- ticker: ICU
- cik: 0001831868
- company_name: SeaStar Medical Holding Corp
- filed_at: 2025-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/0000950170-25-046069-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1831868/000095017025046069/icu-20250327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046069
- JSON: https://secwatch.observer/filing/0000950170-25-046069.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046069.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.